Side effects often attributed to statins were the same for those taking a placebo

Research Highlights:

• Study participants who reported side effects from cholesterol-lowering medications known as statins also reported the same side effects when they unknowingly took placebo pills.
• These side effects are real, and it appears may be mostly due to the psychological rather than the pharmacological effects of statins since symptoms were consistent when taking the placebo.

Embargoed until 9:28 a.m. CT/10:28 a.m. ET, Sunday, Nov. 15, 2020

(NewMediaWire) – November 15, 2020 – DALLAS, Nov. 15, 2020 — Among patients who stopped taking their cholesterol-lowering statin medication due to side effects, researchers found the statin may not have been the culprit because patients taking a placebo reported the same side effects, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2020. The virtual meeting is Friday, November 13-Tuesday, November 17, 2020, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.

Statins lower LDL (bad) cholesterol. Some people, however, experience side effects such as muscle pain and stop taking the medication.

“We know that many patients are not able to take statins because of side effects such as muscle pain, called myalgia,” said James Philip Howard, M.B., Ph.D., lead study author and a Ph.D. fellow at Imperial College in London. “Prior placebo-controlled randomized trials have not found evidence of what should be an overwhelmingly obvious difference in side effect symptoms while a person is taking statins rather than taking a placebo. This randomized study allowed us to examine participants’ symptoms when they were off all tablets and compare them with symptoms occurring when on statin therapy vs. placebo therapy.”

The Self-Assessment Method for Statin Side-effects Or Nocebo (SAMSON) Trial measured patients’ self-reported symptoms throughout a 12-month period of randomly alternating months of statin use, placebo and no medications. The study, conducted in London, enrolled adults who had previously taken one or more statins but stopped taking them due to side effects.

About 60 people completed the study, which involved four months of a statin, four months of placebo and four months of neither. At the start of the study, the participants were each given 12 medication jars: four contained statins (20 mg daily of atorvastatin), four contained placebos and four were empty. At the beginning of each month, they opened and started a new jar without knowing what the jar contained. Study participants tracked the intensity of their symptoms daily on a smart phone and ranked them on a scale from zero (“no symptoms”) to 100 (“worst imaginable”). The participants could stop the tablets for the month if the symptoms became intolerable.

Researchers found:

• 90% of the symptoms that were reported when participants were taking a statin were also reported when the participants unknowingly took the placebo tablets.
• Patients were just as likely to need to temporarily stop placebo tablets due to intolerable side effects as the statin tablets.

This could point to a psychological rather than pharmacological effect of statins, the researchers noted.

“Patients should be taken seriously when they report side effects, because they are genuinely suffering,” Howard said. “We were surprised how severe some of the symptoms experienced during the study were. Twenty-four patients, on 71 occasions, had symptoms so severe they had to stop taking their tablets temporarily. However, this occurred just as frequently when patients took a placebo as when they took a statin.”

Researchers also noted that six months after the participants completed the trial, half of them had restarted taking a statin medication and were still taking it.

“The design of the trial – alternating statin, placebo and no-treatment periods – can help patients explore the symptoms they suffer when taking a medication like a statin,” Howard said.

Study limitations include that researchers could only recruit patients who developed their previous statin symptoms within two weeks of starting the tablets. In addition, they tested only a single statin at a single dose (atorvastatin 20mg daily), and the trial did not require blood samples to avoid discouraging participation, prevent delays to stopping tablets and maximize clinical applicability.

Joint first author is Frances Wood, M.Phil. Other co-authors are Judith Finegold, Ph.D.; Alexandra Nowbar, M.B.B.S.; David Thompson, Ph.D.; Ahran D. Arnold, M.B.B.S.; Christopher Rajkumar, M.B.B.S.; Christopher B. Stride, Ph.D.; Susan Connolly, Ph.D.; Jaimini Cegla; Peter Sedgwick Sever, F.R.C.P.; Christine Norton, Ph.D.; Simon Thom, M.D.; Matthew Shun-Shin, Ph.D.; and Darrel Francis, M.A., M.B., B.Chir., M.D., F.R.C.P. Author disclosures are in the abstract. The study was funded by The British Heart Foundation.

Presentation: Session: Fish Oil, Fancy Drugs, and Frustrations in Lipid Management

Additional Resources:

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here. 

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

###

For Media Inquiries and AHA Expert Perspective:

AHA News Media in Dallas: 214-706-1173; ahacommunications@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org